secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001558370-22-002470
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q4 net loss $93.3M; UKONIQ revenue $2.3M; FDA partial hold on U2
--------------------------------------------------------------------------------

- Net loss Q4 2021 $93.3M ($88.2M Q4 2020); full year net loss $348.1M ($279.4M 2020).
- Product revenue from UKONIQ net $2.3M in Q4, $6.5M for full year 2021.
- Cash, equivalents & securities $350.3M at Dec 31, 2021; funds operations into 2023.
- FDA partial clinical hold on U2 (ublituximab + umbralisib) studies in CLL/NHL; ODAC meeting expected March/April 2022.
- FDA accepted BLA for ublituximab in RMS (PDUFA Sept 28, 2022); BLA/sNDA for U2 in CLL/SLL pending ODAC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022002470/0001558370-22-002470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022002470/tgtx-20220301x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-002470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer